Ronen Israel and Amrik Shah join an expanded international leadership group at Yaqrit preparing to implement funding streams and build pharmaceutical partnerships to propel the company’s drug products ...

Natural Chromium Picolinate- this ingredient helps you control hunger and food cravings. Additionally, it makes your system ...

Menopausal support (energy, mood, muscle retention): creatine is a woman’s powerful ally during the menopause face as it ...

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite. Plan to ...

The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $5.0 million. The Company intends to use the net ...

In February 2025, Belite completed a registered direct offering priced at the market, raising gross proceeds of $15 million, with the potential for additional proceeds of approximately $15 million ...

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be ...

Neo Medical Inc., a cutting-edge innovator in handheld ultrasound technology, and the POCUS Certification Academy, a globally recognized provider of point-of-care ultrasound (POCUS) education and ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children ...

The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor’s StealthX™ exosome vaccine in the third quarter of 2025, subject to NIAID’s ...

THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update ...

Pending regulatory authorization, Fractyl expects to dose the first patients with RJVA-001 and report preliminary data in 2026, which the Company believes could lead to a potentially first-in-class, ...